What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott Vascular; Natera; Paragonix; NupulseCV; Fineheart; Janssen; Moderna
• Equity/Stock(s)/Options - Transmedics; Leviticus